查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1918706

碳青霉烯类抗生素市场按分子、剂型、给药途径、适应症、通路和最终用户划分－2026-2032年全球预测

4-AA for Carbapenem Antibiotic Market by Molecule, Dosage Form, Route, Indication, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年，4-AA 在碳青霉烯类抗生素市场的市场规模为 9,376 万美元，预计到 2026 年将成长至 1.0714 亿美元，年复合成长率为 8.17%，到 2032 年将达到 1.6254 亿美元。

关键市场统计数据
基准年 2025 9376万美元
预计年份：2026年 1.0714亿美元
预测年份 2032 1.6254亿美元
复合年增长率 (%) 8.17%

对碳青霉烯类药物的临床效用、製剂趋势、管理压力以及对医疗政策制定者的策略意义进行全面的基本概述。

碳青霉烯类抗生素因其对严重多重抗药性感染疾病的频谱疗效而备受推崇，在现代抗菌治疗中发挥关键作用。临床医生依靠碳青霉烯类抗生素来挽救复杂腹腔感染疾病、严重尿道感染感染、细菌性脓毒症和医院获得性肺炎等疾病患者的生命，而医疗系统也将其视为抗菌药物管理计划的重要组成部分，以维持治疗选择。在此临床背景下，分子创新、製剂多样化和供应链韧性的进步正在改变医院、诊所和门诊手术中心采购和使用碳青霉烯类抗生素的方式。

监管趋严、优先发展抗生素管理以及物流创新如何重塑碳青霉烯类药物的使用趋势和竞争格局

受临床实践、监管收紧和供应链优先事项演变的影响，碳青霉烯类抗生素的市场环境正在经历变革性变化。人们对抗菌素抗药性的日益关注促使药物使用更加註重靶向性，而世界各地的监管机构也在加强对药物安全性和上市后监测的审查，迫使生产商强化风险缓解策略并投资建设完善的药物监测系统。

2025年美国关税政策和贸易调整促使抗生素采购设计审查、供应连续性计画和策略采购审查

美国关税政策的改变和贸易行动为关键抗生素的筹资策略带来了新的复杂性。进口关税的提高、某些药品成分的重新分类以及海关程序的行政调整，都在改变到岸成本的计算方式，并凸显了本地持续供应的重要性。因此，采购团队正在重新审视其供应商组合，权衡国内生产伙伴关係的优势与跨国供应链网路的柔软性。

详细的細項分析揭示了分子变异、剂型配置、通路、给药途径、适应症和最终用户类型如何影响产品适用性和采购决策。

精细的细分观点揭示了不同分子、剂型、通路、给药途径、适应症和最终用户所面临的独特机会和挑战。具体到每种分子，这涵盖了比阿培南、多利培南、厄他培南、Imipenem、Meropenem和帕尼培南，每种分子都具有独特的临床特性、抗药性谱和製剂挑战，这些都会影响医院的处方集决策和治疗路径。剂型方面的考量进一步区分了不同的产品：胶囊、注射液、注射粉剂和片剂会影响临床工作流程的实际情况，其中註射液分为安瓿瓶和管瓶两种规格，注射粉剂则以预填充式注射器和管瓶的形式供应，这会影响床边配药时间、储存和护理工作量。

区域比较趋势表明，美洲、欧洲、中东和非洲以及亚太地区都需要针对不同的监管、分销和商业化策略采取量身定制的方法。

区域趋势对製造商、经销商和医疗服务提供者提出了不同的策略要求。在美洲，医疗系统重视健全的采购框架、整合的医院网络以及强大的私人支付方，这些支付方要求将经过验证的治疗方法纳入处方笺，并确保稳定的供应。该地区的相关人员优先考虑遵守当地法规和灵活的采购流程，以维持急诊护理的连续性。

透过分子创新、配方改进、策略合作和可靠的分销管道实现差异化竞争优势，从而推动处方集的采纳和客户维繫。

竞争优势源自于分子差异化、製剂创新、监管优势及通路的综合作用。主要企业正致力于透过提升产品稳定性和给药途径来增强其产品特性，同时投资收集上市后安全性数据，以满足日益增长的监管要求。那些将临床开发与医院工作流程要求和药物管理计划相结合的企业，往往能够获得更稳固的处方集地位和长期的临床认可。

为实现永续的市场进入，需采取整合的策略步骤，包括配方创新、供应链韧性、证据产生和客製化商业模式。

产业领导者应采取产品创新、供应链韧性和相关人员参与相结合的综合策略，以充分利用不断变化的临床和采购趋势。优先改善配方和给药方式，使其能够无缝融入医院工作流程，缩短配製时间，提高稳定性，同时支持药物管理目标。投资于预填充配方和易于使用的管瓶/安瓿设计，有助于减轻给药负担，并提高在急诊环境中的应用率。

为了确保研究结果可重复且实用，我们采用透明的调查方法，结合关键相关人员访谈、二手证据评估、主题编码和情境分析。

本执行摘要的研究整合了对关键相关人员的访谈、二手文献综述以及对临床实践趋势和采购机制的结构化分析。主要资讯来源包括与临床医生、医院药房主任、采购专业人员和分销合作伙伴的对话，以收集有关临床偏好、管理流程和采购限制的实地见解。这些定性资讯与已发布的监管指南、临床治疗通讯协定和白皮书分析进行了三角验证，以确保其符合当前的医疗标准。

本文综合分析了各项策略要务，阐明了为何临床疗效、营运可行性和监管准备的协调一致对于碳青霉烯类药物领域的持续成功至关重要。

总之，碳青霉烯类药物治疗领域正处于一个转折点，临床需求、监管审查和物流现实相互交织，迫使商业和营运策略进行重组。有效整合製剂改进、可靠的实证项目和灵活的分销模式的相关人员，将在医院、诊所和门诊手术中心实现持续应用方面获得优势。同时，不断变化的贸易政策也凸显了灵活的采购计划以及生产商和医疗采购方之间密切合作的必要性。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 碳青霉烯类抗生素市场：依分子分类

  • 比阿培南
  • 多利培南
  • 厄他培南
  • Imipenem
  • Meropenem
  • 帕尼培南

9. 碳青霉烯类抗生素市场（以剂型划分）

  • 胶囊
  • 注射液
    • 安瓿
    • 管瓶
  • 注射用粉剂
    • 预填充式注射器
    • 管瓶
  • 药片

10. 依给药途径分類的碳青霉烯类抗生素市场

  • 静脉注射
  • 口服

11. 依适应症分類的碳青霉烯类抗生素市场

  • 细菌性败血症
  • 复杂的腹腔内感染疾病
  • 复杂性尿道感染
  • 院内肺炎

12. 碳青霉烯类抗生素市场（依分销通路划分）

  • 直接竞标
    • 政府竞标
    • 私人竞标
  • 医院药房
    • 私立医院药房
    • 公立医院药房
  • 网路药房
    • 厂商直销平台
    • 第三方平台
  • 零售药房
    • 连锁药局
    • 独立药房

13. 依最终用户分類的碳青霉烯类抗生素市场

  • 门诊手术中心
    • 一般医学
    • 单一专科
  • 诊所
    • 一般诊所
    • 专科诊所
  • 医院
    • 私立医院
    • 公立医院

第十四章 碳青霉烯类抗生素市场：依地区划分

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 碳青霉烯类抗生素市场（依类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

16. 各国碳青霉烯类抗生素市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国碳青霉烯类抗生素市场

第十八章 中国碳青霉烯类抗生素市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AstraZeneca plc
  • Asymchem Laboratories（Tianjin）Co., Ltd.
  • Aurobindo Pharma Ltd.
  • Daewoong Pharmaceutical Co., Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Fresenius Kabi AG
  • Gland Pharma Limited
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals PLC
  • Lupin Limited
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sandoz AG
  • Shionogi & Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-F14BA1B33FDC

The 4-AA for Carbapenem Antibiotic Market was valued at USD 93.76 million in 2025 and is projected to grow to USD 107.14 million in 2026, with a CAGR of 8.17%, reaching USD 162.54 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 93.76 million
Estimated Year [2026] USD 107.14 million
Forecast Year [2032] USD 162.54 million
CAGR (%) 8.17%

Comprehensive foundational overview of carbapenem clinical utility, formulation dynamics, stewardship pressures, and strategic implications for healthcare decision-makers

The carbapenem class occupies a pivotal role in contemporary antimicrobial therapy, prized for broad-spectrum efficacy against severe and multidrug-resistant bacterial infections. Clinicians rely on carbapenems for life-saving interventions in complicated intra-abdominal infections, severe urinary tract infections, bacterial sepsis, and hospital-acquired pneumonia, while healthcare systems view them as critical components of stewardship programs intended to preserve therapeutic options. Against this clinical backdrop, developments in molecule innovation, formulation diversity, and supply chain resilience are reshaping how hospitals, clinics, and ambulatory surgical centers source and deploy carbapenem therapies.

This executive summary synthesizes clinical utility, regulatory drivers, distribution dynamics, and competitive positioning in a manner that supports strategic planning. It highlights how formulation choices-ranging from injectable solutions to oral administration where relevant-interact with hospital procurement processes and ambulatory care requirements. Further, it underscores the intersection of antimicrobial stewardship imperatives and commercial strategies, noting that stewardship protocols influence prescribing patterns even as manufacturers pursue differentiated delivery formats and molecule variants. By grounding the analysis in clinical priorities and healthcare operational realities, the introduction frames subsequent sections to support actionable decisions by clinical leaders, procurement directors, and commercial strategists.

How evolving regulatory rigor, antimicrobial stewardship priorities, and logistical innovations are reshaping adoption dynamics and competitive positioning in the carbapenem space

The landscape for carbapenem antibiotics is undergoing transformative shifts driven by clinical practice, regulatory rigor, and evolving supply chain priorities. Increasing attention to antimicrobial resistance is sharpening the focus on targeted use, while regulatory authorities worldwide are tightening scrutiny of safety profiles and post-market surveillance, prompting manufacturers to enhance risk mitigation strategies and invest in robust pharmacovigilance frameworks.

Simultaneously, innovation in molecule development and dosage form engineering is broadening therapeutic options. Manufacturers are prioritizing formulation advances that improve stability, ease of administration, and compatibility with existing hospital systems. These advances interact with procurement and distribution models, prompting hospitals and clinics to reassess stockholding practices and cold-chain logistics. Digital procurement platforms and manufacturer-owned distribution channels are gaining prominence, enabling more responsive supply replenishment and improved visibility across tenders and hospital pharmacies.

Collectively, these shifts are producing a more dynamic environment in which clinical guidelines, stewardship imperatives, and logistical robustness determine which products achieve durable adoption. Market participants that adapt to higher regulatory standards, offer differentiated delivery formats, and integrate with modern procurement infrastructures will find clearer pathways to long-term clinical acceptance and operational resilience.

United States tariff policies and trade adjustments in 2025 that are prompting procurement redesigns, supply continuity planning, and strategic sourcing recalibrations for antimicrobials

Tariff policy changes and trade measures in the United States are introducing a new dimension of complexity to sourcing strategies for critical antimicrobials. Increased import duties, reclassification of certain pharmaceutical inputs, and administrative adjustments to customs procedures have altered landed cost calculations and amplified the importance of local supply continuity. As a result, procurement teams are recalibrating supplier mixes, weighing the benefits of domestic manufacturing partnerships against the flexibility of multinational supply networks.

These policy shifts have ripple effects beyond immediate pricing. They influence inventory planning, prompting larger safety stocks or strategic vendor consolidation to mitigate customs-related delays. Regulatory compliance requirements tied to import permits and documentation have also intensified, requiring closer collaboration between manufacturers, distributors, and hospital procurement departments. In addition, purchasers are exploring alternative distribution channels to bypass potential bottlenecks, including direct tender arrangements and manufacturer-operated platforms that can offer improved traceability and expedited fulfillment.

Taken together, tariff dynamics are catalyzing a strategic reassessment of supply chain models. Organizations that proactively redesign procurement workflows, strengthen domestic partnerships, and enhance demand forecasting capabilities will be better positioned to preserve clinical continuity while managing the operational impacts of trade policy changes.

Deep segmentation analysis revealing how molecule variants, dosage configurations, distribution channels, routes, indications, and end-user types shape product suitability and procurement decisions

A nuanced segmentation perspective illuminates distinct opportunities and constraints across molecules, dosage forms, distribution pathways, routes of administration, indications, and end users. Based on molecule, the landscape spans Biapenem, Doripenem, Ertapenem, Imipenem, Meropenem, and Panipenem, each presenting unique clinical attributes, resistance profiles, and formulation challenges that influence hospital formulary decisions and therapeutic pathways. Dosage form considerations further differentiate offerings: capsule, injection solution, powder for injection, and tablet formats interact with clinical workflow realities, with injection solutions subdivided into ampoule and vial configurations and powder for injection available as pre-filled syringes and vials, thereby affecting bedside preparation time, storage, and nursing workload.

Distribution channel segmentation shapes accessibility and procurement complexity, as markets are served through direct tender arrangements, hospital pharmacies, online pharmacies, and retail pharmacies. Direct tenders can be issued by government or private purchasers, hospital pharmacies may be public or private institutions, online pharmacies operate on manufacturer-owned or third-party platforms, and retail distribution includes both chain and independent pharmacies-each channel introducing different contracting norms, compliance obligations, and inventory practices. End-user segmentation highlights clinical demand drivers across ambulatory surgical centers, clinics, and hospitals, with ambulatory surgical centers differentiated into multi-specialty and single-specialty operations, clinics segmented into general and specialty practices, and hospitals categorized as private or public institutions. Route segmentation into intravenous and oral administration further informs clinical protocol alignment and supply chain requirements. Finally, indication-focused segmentation across bacterial sepsis, complicated intra-abdominal infection, complicated urinary tract infection, and hospital-acquired pneumonia clarifies therapeutic prioritization and formulary placement, enabling manufacturers and health systems to better align product attributes to clinical need.

Comparative regional dynamics showing how Americas, Europe Middle East & Africa, and Asia-Pacific each demand tailored regulatory navigation, distribution, and commercialization strategies

Regional dynamics create differentiated strategic imperatives for manufacturers, distributors, and healthcare providers. In the Americas, healthcare systems emphasize robust procurement frameworks, integrated hospital networks, and a strong private payer presence that drives demand for formulary-proven therapies and reliable supply. Stakeholders in this region are prioritizing local regulatory alignment and procurement agility to maintain continuity for acute care settings.

Europe, Middle East & Africa presents a heterogeneous landscape where regulatory convergence and varying public procurement practices coexist with significant disparities in healthcare infrastructure. In many markets, public tenders and centralized purchasing play decisive roles, while in others private healthcare growth and localized distribution networks introduce varied commercialization strategies. Regional complexities also elevate the importance of adaptable packaging and cold-chain solutions to meet diverse logistical environments.

Asia-Pacific combines rapid clinical uptake with varied payer mechanisms and expanding hospital capacity, spurring demand for both established molecules and new delivery formats. The region's manufacturing base and evolving regulatory frameworks offer pathways to strengthen local production and reduce import dependency. Across all three regions, stakeholders must balance regulatory compliance, distribution reliability, and clinical acceptance to succeed in increasingly competitive and operationally demanding markets.

Competitive differentiation through molecule innovation, formulation enhancements, strategic partnerships, and distribution reliability that drive formualry acceptance and customer retention

Competitive dynamics are driven by a combination of molecule differentiation, formulation innovation, regulatory positioning, and distribution reach. Leading organizations focus on advancing product profiles through stability and delivery improvements while investing in post-marketing safety evidence to meet heightened regulatory expectations. Companies that align clinical development with hospital workflow requirements and stewardship programs tend to achieve stronger formulary positioning and longer-term clinical acceptance.

Strategic partnerships between manufacturers, contract manufacturing organizations, and regional distributors are increasingly common as firms seek to secure capacity, diversify sourcing, and minimize exposure to trade-related disruptions. In parallel, investment in proprietary digital platforms and manufacturer-owned distribution channels is enabling improved inventory visibility and faster fulfillment for hospital tenders and pharmacy networks. Firms that successfully integrate clinical evidence generation with supply reliability and procurement responsiveness will likely sustain competitive advantages.

Moreover, the ability to offer tailored commercial models-such as tender support, training for clinical staff, and bundled service offerings-enhances customer retention among hospitals and clinics. Competitive differentiation is therefore less about singular product attributes and more about the total value proposition combining clinical efficacy, operational convenience, and dependable distribution.

Actionable strategic steps for leaders to align formulation innovation, supply chain resilience, evidence generation, and tailored commercial models for durable market access

Industry leaders should pursue an integrated approach that aligns product innovation, supply chain resilience, and stakeholder engagement to capitalize on evolving clinical and procurement trends. First, prioritize formulation and delivery improvements that reduce preparation time and enhance stability to fit seamlessly into hospital workflows while supporting stewardship objectives. Investing in pre-filled formats and user-friendly vial or ampoule designs can lower administration burden and improve adoption in acute care settings.

Second, strengthen supply chain networks by establishing regional manufacturing partnerships, diversifying supplier bases, and engaging in long-term tender collaborations with major hospital systems. Enhancing traceability through digital platforms and developing contingency plans for tariff-induced disruptions will safeguard continuity for critical therapies. Third, build clinical and regulatory evidence through targeted post-market studies and real-world evidence programs that demonstrate safety and therapeutic value across prioritized indications. These initiatives should be coupled with educational outreach to pharmacy and clinical teams to support appropriate prescribing.

Finally, tailor commercial models to the specific needs of end users and distribution channels, offering flexible contracting, tender support, and integrated logistics services where appropriate. By combining product-level innovation with operational excellence and stakeholder-centric commercial approaches, organizations can strengthen market access and clinical acceptance across diverse healthcare environments.

Transparent methodological approach combining primary stakeholder interviews, secondary evidence appraisal, thematic coding, and scenario analysis to ensure reproducible and actionable insights

The research underpinning this executive summary synthesizes primary stakeholder interviews, secondary literature reviews, and structured analysis of clinical practice trends and procurement mechanisms. Primary inputs included dialogues with clinicians, hospital pharmacy leaders, procurement specialists, and distribution partners to capture frontline insights on clinical preferences, administration workflows, and sourcing constraints. These qualitative inputs were triangulated with published regulatory guidance, clinical treatment protocols, and whitepaper analyses to ensure alignment with prevailing standards of care.

Analytical methods emphasized thematic coding of stakeholder interviews to identify recurring operational pain points and opportunity areas. Scenario analysis was employed to map the implications of trade policy shifts and distribution model innovations on procurement cycles and inventory strategies. Comparative assessments across molecules, dosage formats, and routes of administration used cross-functional validation with clinical and supply chain experts to ensure practical relevance. Throughout the methodology, emphasis was placed on reproducibility and transparency, documenting data sources, interview frameworks, and analytical assumptions to allow readers to interrogate findings and tailor interpretations to their institutional contexts.

Synthesis of strategic imperatives showing why aligning clinical efficacy, operational feasibility, and regulatory readiness is essential for sustained success in the carbapenem domain

In conclusion, the carbapenem therapeutic area stands at an inflection point where clinical imperatives, regulatory scrutiny, and logistical realities converge to reshape commercial and operational strategies. Stakeholders that effectively integrate formulation improvements, robust evidence programs, and resilient distribution models will gain an advantage in achieving durable adoption across hospitals, clinics, and ambulatory surgical centers. At the same time, evolving trade policies underscore the need for agile procurement planning and closer collaboration between manufacturers and healthcare purchasers.

Looking forward, the balance between preserving antimicrobial efficacy through stewardship and meeting immediate clinical needs will remain central to decision-making. Organizations that proactively align product attributes with clinical workflows, invest in supply chain redundancy, and engage in targeted evidence generation will be better equipped to navigate complex tender landscapes and regulatory expectations. Ultimately, success will hinge on holistic strategies that treat clinical efficacy, operational feasibility, and regulatory compliance as interconnected dimensions of product value.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. 4-AA for Carbapenem Antibiotic Market, by Molecule

  • 8.1. Biapenem
  • 8.2. Doripenem
  • 8.3. Ertapenem
  • 8.4. Imipenem
  • 8.5. Meropenem
  • 8.6. Panipenem

9. 4-AA for Carbapenem Antibiotic Market, by Dosage Form

  • 9.1. Capsule
  • 9.2. Injection Solution
    • 9.2.1. Ampoule
    • 9.2.2. Vial
  • 9.3. Powder For Injection
    • 9.3.1. Pre-Filled Syringe
    • 9.3.2. Vial
  • 9.4. Tablet

10. 4-AA for Carbapenem Antibiotic Market, by Route

  • 10.1. Intravenous
  • 10.2. Oral

11. 4-AA for Carbapenem Antibiotic Market, by Indication

  • 11.1. Bacterial Sepsis
  • 11.2. Complicated Intra-Abdominal Infection
  • 11.3. Complicated Urinary Tract Infection
  • 11.4. Hospital-Acquired Pneumonia

12. 4-AA for Carbapenem Antibiotic Market, by Distribution Channel

  • 12.1. Direct Tender
    • 12.1.1. Government Tender
    • 12.1.2. Private Tender
  • 12.2. Hospital Pharmacies
    • 12.2.1. Private Hospital Pharmacies
    • 12.2.2. Public Hospital Pharmacies
  • 12.3. Online Pharmacies
    • 12.3.1. Manufacturer Owned Platforms
    • 12.3.2. Third Party Platforms
  • 12.4. Retail Pharmacies
    • 12.4.1. Chain Pharmacies
    • 12.4.2. Independent Pharmacies

13. 4-AA for Carbapenem Antibiotic Market, by End User

  • 13.1. Ambulatory Surgical Center
    • 13.1.1. Multi Specialty
    • 13.1.2. Single Specialty
  • 13.2. Clinic
    • 13.2.1. General Clinic
    • 13.2.2. Specialty Clinic
  • 13.3. Hospital
    • 13.3.1. Private Hospital
    • 13.3.2. Public Hospital

14. 4-AA for Carbapenem Antibiotic Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. 4-AA for Carbapenem Antibiotic Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. 4-AA for Carbapenem Antibiotic Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States 4-AA for Carbapenem Antibiotic Market

18. China 4-AA for Carbapenem Antibiotic Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AstraZeneca plc
  • 19.6. Asymchem Laboratories (Tianjin) Co., Ltd.
  • 19.7. Aurobindo Pharma Ltd.
  • 19.8. Daewoong Pharmaceutical Co., Ltd.
  • 19.9. Dr. Reddy's Laboratories Ltd.
  • 19.10. Eli Lilly and Company
  • 19.11. Fresenius Kabi AG
  • 19.12. Gland Pharma Limited
  • 19.13. GlaxoSmithKline plc
  • 19.14. Hikma Pharmaceuticals PLC
  • 19.15. Lupin Limited
  • 19.16. Merck & Co., Inc.
  • 19.17. Pfizer Inc.
  • 19.18. Sandoz AG
  • 19.19. Shionogi & Co., Ltd.
  • 19.20. Sun Pharmaceutical Industries Ltd.
  • 19.21. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY MOLECULE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY BIAPENEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY BIAPENEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY BIAPENEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY DORIPENEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY DORIPENEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY DORIPENEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY ERTAPENEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY ERTAPENEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY ERTAPENEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY IMIPENEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY IMIPENEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY IMIPENEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY MEROPENEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY MEROPENEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY MEROPENEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY PANIPENEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY PANIPENEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY PANIPENEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY INJECTION SOLUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY INJECTION SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY INJECTION SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY INJECTION SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY AMPOULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY AMPOULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY AMPOULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY VIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY VIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY POWDER FOR INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY POWDER FOR INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY POWDER FOR INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY POWDER FOR INJECTION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY PRE-FILLED SYRINGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY PRE-FILLED SYRINGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY PRE-FILLED SYRINGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY VIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY VIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY BACTERIAL SEPSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY BACTERIAL SEPSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY BACTERIAL SEPSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY COMPLICATED INTRA-ABDOMINAL INFECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY COMPLICATED INTRA-ABDOMINAL INFECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY COMPLICATED INTRA-ABDOMINAL INFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY COMPLICATED URINARY TRACT INFECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY COMPLICATED URINARY TRACT INFECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY COMPLICATED URINARY TRACT INFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY HOSPITAL-ACQUIRED PNEUMONIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY HOSPITAL-ACQUIRED PNEUMONIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY HOSPITAL-ACQUIRED PNEUMONIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY DIRECT TENDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY DIRECT TENDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY DIRECT TENDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY DIRECT TENDER, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY GOVERNMENT TENDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY GOVERNMENT TENDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY GOVERNMENT TENDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY PRIVATE TENDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY PRIVATE TENDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY PRIVATE TENDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY PRIVATE HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY PRIVATE HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY PRIVATE HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY PUBLIC HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY PUBLIC HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY PUBLIC HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY MANUFACTURER OWNED PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY MANUFACTURER OWNED PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY MANUFACTURER OWNED PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY THIRD PARTY PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY THIRD PARTY PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY THIRD PARTY PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY AMBULATORY SURGICAL CENTER, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY MULTI SPECIALTY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY MULTI SPECIALTY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY MULTI SPECIALTY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY SINGLE SPECIALTY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY SINGLE SPECIALTY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY SINGLE SPECIALTY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY GENERAL CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY GENERAL CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY GENERAL CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY PRIVATE HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY PRIVATE HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY PUBLIC HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY PUBLIC HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY INJECTION SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY POWDER FOR INJECTION, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY DIRECT TENDER, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY AMBULATORY SURGICAL CENTER, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 156. AMERICAS 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY INJECTION SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY POWDER FOR INJECTION, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY DIRECT TENDER, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY AMBULATORY SURGICAL CENTER, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY INJECTION SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY POWDER FOR INJECTION, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY DIRECT TENDER, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY AMBULATORY SURGICAL CENTER, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY INJECTION SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY POWDER FOR INJECTION, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY DIRECT TENDER, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY AMBULATORY SURGICAL CENTER, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY INJECTION SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY POWDER FOR INJECTION, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY DIRECT TENDER, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY AMBULATORY SURGICAL CENTER, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY INJECTION SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY POWDER FOR INJECTION, 2018-2032 (USD MILLION)
  • TABLE 226. MIDDLE EAST 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 228. MIDDLE EAST 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY DIRECT TENDER, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 232. MIDDLE EAST 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. MIDDLE EAST 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY AMBULATORY SURGICAL CENTER, 2018-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 236. MIDDLE EAST 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY INJECTION SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 241. AFRICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY POWDER FOR INJECTION, 2018-2032 (USD MILLION)
  • TABLE 242. AFRICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 243. AFRICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY DIRECT TENDER, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 247. AFRICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 248. AFRICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 249. AFRICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 250. AFRICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY AMBULATORY SURGICAL CENTER, 2018-2032 (USD MILLION)
  • TABLE 251. AFRICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 252. AFRICA 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY INJECTION SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY POWDER FOR INJECTION, 2018-2032 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY DIRECT TENDER, 2018-2032 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY AMBULATORY SURGICAL CENTER, 2018-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 269. GLOBAL 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 270. ASEAN 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. ASEAN 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 272. ASEAN 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 273. ASEAN 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY INJECTION SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 274. ASEAN 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY POWDER FOR INJECTION, 2018-2032 (USD MILLION)
  • TABLE 275. ASEAN 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 276. ASEAN 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 277. ASEAN 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 278. ASEAN 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY DIRECT TENDER, 2018-2032 (USD MILLION)
  • TABLE 279. ASEAN 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 280. ASEAN 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 281. ASEAN 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 282. ASEAN 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 283. ASEAN 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY AMBULATORY SURGICAL CENTER, 2018-2032 (USD MILLION)
  • TABLE 284. ASEAN 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 285. ASEAN 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 286. GCC 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 287. GCC 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 288. GCC 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 289. GCC 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY INJECTION SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 290. GCC 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY POWDER FOR INJECTION, 2018-2032 (USD MILLION)
  • TABLE 291. GCC 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 292. GCC 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 293. GCC 4-AA FOR CARBAPENEM ANTIBIOTIC MARKET SIZE, BY DISTRIBUTION CHANNEL,